CN1251738C - Chinese medicine for treating ashen nail and its preparation method - Google Patents
Chinese medicine for treating ashen nail and its preparation method Download PDFInfo
- Publication number
- CN1251738C CN1251738C CN 03149754 CN03149754A CN1251738C CN 1251738 C CN1251738 C CN 1251738C CN 03149754 CN03149754 CN 03149754 CN 03149754 A CN03149754 A CN 03149754A CN 1251738 C CN1251738 C CN 1251738C
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- preparation
- tinea unguium
- treatment
- rhizoma anemarrhenae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The present invention discloses a traditional Chinese medicine and a preparation method thereof for treating ashen nails. The traditional Chinese medicine is prepared by that common anemarrhena rhizome, Japanese ampelopsis root and platycodon root are mixed and ground according to the proportion and are soaked in acetic acid glacial for 20 to 40 days in a sealing mode at the temperature of 10 to 30 DEG C to be filtered. The present invention has the advantages of short treatment course, obvious effects, easy use, thoroughly radical cure and difficult recurrence.
Description
Technical field
The present invention relates to the dermopathic medicine of a kind of treatment, relate in particular to Chinese medicine of a kind of treatment tinea unguium (tinea manus and pedis) and preparation method thereof.
Background technology
Tinea unguium (tinea manus and pedis) is the common skin disease, and infection velocity is fast, and it mostly is dermatophytes and the skin bacterium concurrent infection causes.This disease sickness rate also has the trend that rises year by year at present.Treatment tinea unguium (tinea manus and pedis) though the method for treatment is many, can only reach recent clinical effectiveness mainly based on medicine mostly, and easily recurrence is difficult to radical cure.Western medicine adopts 17-hydroxy-11-dehydrocorticosterone or cellular immunization inhibitor more, as bimolane, aminopterin etc., though this class medicine has short term effect preferably, this class medicine is suppressing the synthetic while of DNA, because the dialogue cell killing is too much, so reminded forbidding or careful usefulness, the disadvantage that they exist is epidermis and the corium attenuation that life-time service can make skin, and can cause serious toxicity such as telangiectasis and addiction, and complication is many, subject range is little, and price is also relatively more expensive; Though the maximum side effect of hormone then is the effect that can obtain a period of time, the hormonal system of its body of drug withdrawal is prone to generation " knock-on " phenomenon, and primary disease is sunk deeper and deeper.
The dermopathic medicine for external use a multitude of names of state's internal therapy tinea manus and pedis is as " PIYANPING ", " PIKANG SHUANG ", " PIKANGWANG ", " daktarin " or the like.But because a lot of dermatosis all is to merge fungal infection after merging bacterial infection or bacterial skin infections behind the fungal infection, and fungus or antibacterial can not be killed or suppress to above listed multiple ointment all simultaneously.For example, " PIKANGWANG " is the dermopathic synthetic plaster of a kind of treatment, its active ingredient is ketoconazole and believes his element, it still can to the ringworm effect that is caused by fungal infection, but to by bacterial, perhaps the dermatosis that is caused by fungus and antibacterial concurrent infection is as " blister tinea pedis ", and effect is not good enough; Again for example, " daktarin " is the emulsifiable paste that a kind of miconazole is made, and its anti-mycotic efficiency is very outstanding, but to because of the dermatosis of allergy or mixed infection invalid.
Summary of the invention
The purpose of this invention is to provide the dermopathic medicine of a kind of treatment, Chinese medicine of a kind of treatment tinea unguium (tinea manus and pedis) and preparation method thereof especially is provided, it is serious to have overcome present western medicine toxicity, the shortcoming that treatment by Chinese herbs exists uncertain therapeutic efficacy to cut.
The objective of the invention is to be achieved through the following technical solutions:
A kind of Chinese medicine for the treatment of tinea unguium comprises following component: the Rhizoma Anemarrhenae, Radix Ampelopsis, Radix Platycodonis; Described component can be following parts by weight of component: Rhizoma Anemarrhenae 30-70, Radix Ampelopsis 30-70, Radix Platycodonis 30-70; Be preferably: Rhizoma Anemarrhenae 40-60, Radix Ampelopsis 40-60, Radix Platycodonis 40-60; Be preferably the Rhizoma Anemarrhenae 50, Radix Ampelopsis 50, Radix Platycodonis 50;
The Chinese medicine of described treatment tinea unguium can be made into said external preparation for skin dosage form on any pharmaceutics, especially is oil preparation, Emulsion, cream, dip-coating agent, unguentum, spray, tincture, mixture, water preparation, all agent.
A kind of preparation method of Chinese medicine for the treatment of tinea unguium may further comprise the steps: the Rhizoma Anemarrhenae, Radix Ampelopsis, Radix Platycodonis mixed according to the above ratio, grinds, be soaked in the glacial acetic acid, and soaking temperature 10-30 ℃, soak sealing 20-40 days, filter, promptly;
The described 0.01 μ m-2 μ m that is filtered into;
The preferred 15-25 of described soaking temperature ℃, best 20 ℃;
Described immersion seals preferred 25-35 days, best 30 days;
Described glacial acetic acid concentration is 20-40%, is preferably 25-35%, best 30%.
Described method also comprises by the conventional topical agent preparation of skin method makes various dosage forms, fill, sterilization.
The raw material Rhizoma Anemarrhenae of the present invention: the nature and flavor bitter cold, energy clearing away heat-fire, YIN nourishing are moistened hot-tempered, and be external on probation, and fungus and Candida albicans are had inhibitory action;
Radix Ampelopsis: the nature and flavor hardship is slightly cold, and the energy heat-clearing and toxic substances removing is external on probation, and epidermophyton rubrum is had inhibitory action;
Radix Platycodonis: the nature and flavor bitter cold, the energy heat-clearing and toxic substances removing, external on probation, acrothesium floccosum there is inhibitory action.
It is extremely strong that the Chinese medicine that the present invention treats tinea manus and pedis has penetration, can kill the function of the fungus and the antibacterial of shallow epidermis and depths in the short period of time fast and effectively, cures mainly tinea manus and pedis.
The present invention has the following advantages:
1, compare with present similar medicine, have short treating period, instant effect, easy to use, thoroughly radical cure is difficult for the advantage that recurs.
2, the Chinese medicine of treatment tinea manus and pedis of the present invention is proved repeatedly through clinical for many years, proves that curative effect of medication of the present invention is reliable, and is nontoxic, has no side effect, and can effect a radical cure this disease.
3, the Chinese medicine of treatment tinea manus and pedis of the present invention prove to have significant penetration through clinical demonstration repeatedly for many years, and can be directly quick fungus and the antibacterial that thoroughly kill the shallow and depths of skin table can reach curative effect in the short period of time.
For proving above-mentioned effect of the present invention, carried out following zoopery and clinical trial:
One, following experiment can illustrate the synergism and the potentiation of pharmaceutical composition of the present invention
1. experiment in vitro---the external antibacterial action to several frequently seen pathomycete and part antibacterial (representing bacterium) of pharmaceutical composition of the present invention and component thereof compares, by measuring its minimal inhibitory concentration (MIC), prove the bacteriostasis to fungus of the present invention, reach killing action fungus and antibacterial.
1.1 materials and methods
1.1.1 strain
Fungus, antibacterial are drawn from Guta District Chinese and Western, Jinzhou City, Liaoning Province hospital dermatology department.
1.1.2 culture medium
Fungi culture medium is the Sha Shi broth bouillon, and by mainly being made up of 1% peptone and 2% glucose, PH is 6-6.5; Bacteria culture media is an ordinary broth, and PH is 7.
1.1.3 the preparation of medicinal liquid culture medium
In the different ratio preparation of the described present composition.Each composite formula with the dissolving of 1ml 95%L alcohol, adds sterile distilled water to 5ml earlier again; Respectively draw above-mentioned dosing 0.2ml then, be added to respectively in the culture medium of 1.8ml, shake up the medicinal liquid culture medium that the back two-fold dilution goes out variable concentrations.During experiment, add bacterium liquid 0.02ml among every pipe medicinal liquid culture medium 1ml; 1ml contains dermatophytes 10
5-10
6Individual or yeast-like fungi 10
3-10
4Individual.Be put in after shaking up in 28 ℃ of incubators and cultivated 120-168 hour, wherein yeast-like fungi is 48 hours, observed result.
1.1.4 drug effect criterion
The limpid medicine blank pipe that is same as of meat soup is for there being the bactericidal action of pressing down; Meat soup is obviously muddy, or the Mycoderma growth is arranged, then for there not being the bactericidal action of pressing down.
1.1.5 the mensuration of bacteriocidal concentration
This method is used the agar tilt-pour process.Earlier pharmaceutical composition of the present invention is made into and contains variable concentrations medicinal liquid culture medium, 0.01 μ g/ml-100 μ g/ml; Every again ml adds the test bacterium respectively, and the bacterium amount is 10
3-10
6Individual (ml) acts on 5 minutes, and the 0.1ml that takes a sample respectively inoculates sub-plate, pours sabouraud's agar into, fully shakes up, and cultivates 5-10 days; Count plate and statistical result.
1.2 experimental result
1.2.1 the external effect of compositions and component thereof to common pathomycete (representing bacterium)
Compositions and its component Rhizoma Anemarrhenae, Radix Ampelopsis, Radix Platycodonis comparison shows that to common pathomycete (representing bacterium) bacteriostatic test, compositions is 3～7: 3～7 weight portion proportioning ratio compositionss are lower to the minimal inhibitory concentration (MIC) of several frequently seen pathomycete, effect is strong (seeing Table 1), the proof compositions is better than its one pack system medicine, and antifungal has synergism.
1.2.2 the external effect of compositions and component thereof to common malignant bacteria (representing bacterium)
Compositions and its component Rhizoma Anemarrhenae, Radix Ampelopsis, Radix Platycodonis comparison shows that to common malignant bacteria (representing bacterium) bacteriostatic test, compositions is 3～7: the minimal inhibitory concentration (MIC) to several frequently seen pathomycete during 3～7 weight portion proportionings is also lower, effect is strong (seeing Table 2), the proof compositions is better than its one pack system medicine, and antifungal has synergism.
1.2.3 compositions and component thereof are to the bactericidal action of common malignant bacteria in 5 minutes and fungus (representing bacterium)
Measure the bactericidal action of the compositions and the component Rhizoma Anemarrhenae thereof, Radix Ampelopsis, Radix Platycodonis to common malignant bacteria of 3 strains and fungus, the result shows, compositions is 3～7: 3～7 weight portion proportionings have bactericidal action preferably (seeing Table 3), malignant bacteria is represented bacterium, composition effect is not less than its component, still has kill bacteria effect preferably; Fungus is represented bacterium, and compositions is better than its component, and killing fungus has synergism.
The external bacteriostasis of table 1 present composition variable concentrations to three kinds of common pathomycetes (representing bacterium)
| Minimal inhibitory concentration (MIC, μ g/ml) group | |||
| Epidermophyton rubrum | The purple epidermophyton | Candida albicans | |
| The Rhizoma Anemarrhenae: Radix Ampelopsis: Radix Platycodonis 3: 3: 3 | 1.2 | 1.5 | 8.0 |
| The Rhizoma Anemarrhenae: Radix Ampelopsis: Radix Platycodonis 5: 5: 5 | 1.1 | 1.4 | 7.6 |
| The Rhizoma Anemarrhenae: Radix Ampelopsis: Radix Platycodonis 7: 7: 7 | 1.0 | 1.4 | 7.8 |
| The Rhizoma Anemarrhenae 7 | 8.5 | 7.8 | 10.6 |
| Radix Ampelopsis 7 | 5.8 | 8.8 | 14.6 |
| Radix Platycodonis 7 | 8.7 | 7.8 | 15.2 |
Annotate: 1. table tinea bacterium was cultivated 140 hours, and Candida albicans is cultivated 48 hours observed results.
The external bacteriostasis of table 2 present composition variable concentrations to three kinds of common malignant bacterias (representing bacterium)
| Group | Minimal inhibitory concentration (MIC, μ g/ml) | ||
| Staphylococcus aureus | Staphylococcus epidermidis | Escherichia coli | |
| The Rhizoma Anemarrhenae: Radix Ampelopsis: Radix Platycodonis 3: 3: 3 | 7.2 | 15.4 | 15.7 |
| The Rhizoma Anemarrhenae: Radix Ampelopsis: Radix Platycodonis 5: 5: 5 | 6.5 | 14.4 | 15.1 |
| The Rhizoma Anemarrhenae: Radix Ampelopsis: Radix Platycodonis 7: 7: 7 | 7.0 | 14.3 | 15.1 |
| The Rhizoma Anemarrhenae 7 | 14.5 | 20.8 | 20.6 |
| Radix Ampelopsis 7 | 15.8 | 28.8 | 27.6 |
| Radix Platycodonis 7 | 18.7 | 27.8 | 26.2 |
Annotate: 1. table tinea bacterium was cultivated 140 hours, and Candida albicans is cultivated 48 hours observed results.
Table 3 compositions is to three kinds of common malignant bacterias and 5 minutes sterilizing rate of fungus
| Group | 5 minutes sterilizing rate (%) of medicine bacterium effect | ||
| Epidermophyton rubrum | The purple epidermophyton | Candida albicans | |
| The Rhizoma Anemarrhenae: Radix Ampelopsis: Radix Platycodonis 3: 3: 3 | ＞95.0 | ＞95.0 | ＞95.0 |
| The Rhizoma Anemarrhenae: Radix Ampelopsis: Radix Platycodonis 5: 5: 5 | ＞99.5 | ＞99.5 | ＞99.5 |
| The Rhizoma Anemarrhenae: Radix Ampelopsis: Radix Platycodonis 7: 7: 7 | ＞99.9 | ＞99.9 | ＞99.9 |
| The Rhizoma Anemarrhenae 7 | ＞50.0 | ＞50.0 | ＞60.0 |
| Radix Ampelopsis 7 | ＞65.0 | ＞65.0 | ＞55.0 |
| Radix Platycodonis 7 | ＞69.0 | ＞69.0 | ＞60.9 |
Annotate: 1. the total composition of various ratios is 100 μ g/ml when testing.
Described experiment shows, the present composition is to having significant bactericidal action to common malignant bacteria such as epidermophyton rubrum, purple epidermophyton, staphylococcus aureus and fungus such as Candida albicans.
The inventor has carried out treatment to 220 routine cases with present composition Chinese medicine and has observed, and efficacy result is that cure rate is more than 90%; Effective percentage is more than 90%; Invalid: below 1%.General low-grade infection person uses can heal in 3-5 days.The severe infection person can be healed in 5-10 days.
Present composition Chinese medicine using method: after washing trick every night, use the cotton swab dip in liquid medicine,, apply and wipe about 5 minutes natural airings repeatedly in the affected part.Drug therapy tinea manus and pedis medicine of the present invention is being used in attention, if there is chafing in the tinea manus and pedis affected part, phenomenon such as fester has the aculea pain, and your tinea manuum and tinea pedis exist simultaneously, can treat simultaneously, to reach the purpose of thoroughly killing fungus and antibacterial, avoid cross infection and recur, in therapeutic process, the heavier article of alkalescence can be avoided contacting in the affected part, as detergent, detergent, cement, alkali etc.
The specific embodiment
Embodiment 1
Solution
Take by weighing each component (kg) by following proportioning: the Rhizoma Anemarrhenae 50, Radix Ampelopsis 50, Radix Platycodonis 50;
Preparation method may further comprise the steps: the Rhizoma Anemarrhenae, Radix Ampelopsis, Radix Platycodonis are mixed according to the above ratio, grind, soak 30% in glacial acetic acid, 20 ℃ of soaking temperatures soak sealing 30 days, filter 0.01 μ m, fill, and steam sterilization, promptly.
Embodiment 2
The solution spray agent
Take by weighing each component (kg) by following proportioning: the Rhizoma Anemarrhenae 30, Radix Ampelopsis 30, Radix Platycodonis 30;
Preparation method may further comprise the steps: the Rhizoma Anemarrhenae, Radix Ampelopsis, Radix Platycodonis are mixed according to the above ratio, grind, soak 20% in glacial acetic acid, 15 ℃ of soaking temperatures soak sealing 25 days, filter 2 μ m, the fill spray bottle, and steam sterilization, promptly.
Embodiment 3
Unguentum
Take by weighing each component (kg) by following proportioning: the Rhizoma Anemarrhenae 70, Radix Ampelopsis 70, Radix Platycodonis 70;
Preparation method, may further comprise the steps: the Rhizoma Anemarrhenae, Radix Ampelopsis, Radix Platycodonis are mixed according to the above ratio, grind, soak 40% in glacial acetic acid, 25 ℃ of soaking temperatures, soak sealing 35 days, filter 0.5 μ m, add excipient octadecanol 5kg, stearic acid 9kg, glyceryl monostearate 4kg, vaseline 3kg, glycerol 9kg, triethanolamine 0.1kg and surplus distilled water are mixed with unguentum, fill, 10 grams/, 100 ℃ of steam sterilizations 15 minutes are promptly.
Embodiment 4
Oil preparation
Take by weighing each component (kg) by following proportioning: the Rhizoma Anemarrhenae 40, Radix Ampelopsis 40, Radix Platycodonis 40;
Preparation method, may further comprise the steps: the Rhizoma Anemarrhenae, Radix Ampelopsis, Radix Platycodonis are mixed according to the above ratio, grind, soak 35% in glacial acetic acid, 22 ℃ of soaking temperatures, soak sealing 26 days, filter 1 μ m, add glycerol 6kg, adding distil water is made 100L, shake up, fill 125ml/ bottle, 100 ℃ of steam sterilizations 20 minutes are promptly.
Embodiment 5
Tincture
Take by weighing each component (kg) by following proportioning: the Rhizoma Anemarrhenae 60, Radix Ampelopsis 60, Radix Platycodonis 60;
Preparation method may further comprise the steps: the Rhizoma Anemarrhenae, Radix Ampelopsis, Radix Platycodonis are mixed according to the above ratio, grind, soak 35% in glacial acetic acid, 22 ℃ of soaking temperatures soak sealing 26 days, filter 1 μ m, add 30L ethanol, 10L propylene glycol, the formulated tincture 100L of 8L glycerol and surplus distilled water.
Claims (9)
1, a kind of Chinese medicine for the treatment of tinea unguium is made by following bulk drugs: Rhizoma Anemarrhenae 30-70, Radix Ampelopsis 30-70, Radix Platycodonis 30-70.
2, according to the Chinese medicine of the treatment tinea unguium of claim 1, it is characterized in that the weight portion of described crude drug is: Rhizoma Anemarrhenae 40-60, Radix Ampelopsis 40-60, Radix Platycodonis 40-60.
3, according to the Chinese medicine of the treatment tinea unguium of claim 2, it is characterized in that the weight portion of described crude drug is: the Rhizoma Anemarrhenae 50, Radix Ampelopsis 50, Radix Platycodonis 50.
4, according to the Chinese medicine of the treatment tinea unguium of claim 1, it is characterized in that described Chinese medicine preparation is oil preparation, Emulsion, cream, dip-coating agent, unguentum, spray, tincture, mixture, water preparation or spirit.
5, according to the described a kind of preparation method of Chinese medicine for the treatment of tinea unguium of arbitrary claim in the claim 1～4, step is as follows: the Rhizoma Anemarrhenae, Radix Ampelopsis, Radix Platycodonis by the described arbitrary mixed of claim 1-3, are ground, be soaked in the glacial acetic acid, sealing was soaked 20-40 days, filtered, promptly.
6, according to the preparation method of Chinese medicine of the treatment tinea unguium of claim 5, described filtration particle diameter is for being 0.01 μ m-2 μ m.
7, according to the preparation method of Chinese medicine of the treatment tinea unguium of claim 5, described soaking temperature is 10-30 ℃.
8, according to the preparation method of Chinese medicine of the treatment tinea unguium of claim 5, described glacial acetic acid concentration is 20-40%.
9, according to the preparation method of Chinese medicine of the treatment tinea unguium of claim 5, described method also comprises by the conventional topical agent preparation of skin method makes various dosage forms, fill, sterilization.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03149754 CN1251738C (en) | 2003-08-05 | 2003-08-05 | Chinese medicine for treating ashen nail and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03149754 CN1251738C (en) | 2003-08-05 | 2003-08-05 | Chinese medicine for treating ashen nail and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1513530A CN1513530A (en) | 2004-07-21 |
| CN1251738C true CN1251738C (en) | 2006-04-19 |
Family
ID=34240506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03149754 Expired - Fee Related CN1251738C (en) | 2003-08-05 | 2003-08-05 | Chinese medicine for treating ashen nail and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1251738C (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9309436B2 (en) | 2007-04-13 | 2016-04-12 | Knauf Insulation, Inc. | Composite maillard-resole binders |
| US9416248B2 (en) | 2009-08-07 | 2016-08-16 | Knauf Insulation, Inc. | Molasses binder |
| US9447281B2 (en) | 2007-01-25 | 2016-09-20 | Knauf Insulation Sprl | Composite wood board |
| US9464207B2 (en) | 2005-07-26 | 2016-10-11 | Knauf Insulation, Inc. | Binders and materials made therewith |
| US9469747B2 (en) | 2007-08-03 | 2016-10-18 | Knauf Insulation Sprl | Mineral wool insulation |
| US9492943B2 (en) | 2012-08-17 | 2016-11-15 | Knauf Insulation Sprl | Wood board and process for its production |
| US9493603B2 (en) | 2010-05-07 | 2016-11-15 | Knauf Insulation Sprl | Carbohydrate binders and materials made therewith |
| US9505883B2 (en) | 2010-05-07 | 2016-11-29 | Knauf Insulation Sprl | Carbohydrate polyamine binders and materials made therewith |
| US11846097B2 (en) | 2010-06-07 | 2023-12-19 | Knauf Insulation, Inc. | Fiber products having temperature control additives |
-
2003
- 2003-08-05 CN CN 03149754 patent/CN1251738C/en not_active Expired - Fee Related
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464207B2 (en) | 2005-07-26 | 2016-10-11 | Knauf Insulation, Inc. | Binders and materials made therewith |
| US9447281B2 (en) | 2007-01-25 | 2016-09-20 | Knauf Insulation Sprl | Composite wood board |
| US9309436B2 (en) | 2007-04-13 | 2016-04-12 | Knauf Insulation, Inc. | Composite maillard-resole binders |
| US9469747B2 (en) | 2007-08-03 | 2016-10-18 | Knauf Insulation Sprl | Mineral wool insulation |
| US9416248B2 (en) | 2009-08-07 | 2016-08-16 | Knauf Insulation, Inc. | Molasses binder |
| US9493603B2 (en) | 2010-05-07 | 2016-11-15 | Knauf Insulation Sprl | Carbohydrate binders and materials made therewith |
| US9505883B2 (en) | 2010-05-07 | 2016-11-29 | Knauf Insulation Sprl | Carbohydrate polyamine binders and materials made therewith |
| US11846097B2 (en) | 2010-06-07 | 2023-12-19 | Knauf Insulation, Inc. | Fiber products having temperature control additives |
| US9492943B2 (en) | 2012-08-17 | 2016-11-15 | Knauf Insulation Sprl | Wood board and process for its production |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1513530A (en) | 2004-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1032900C (en) | Metrohidazole formulations and therapeutical uses thereof | |
| CN107812137A (en) | A kind of draft skin bacteriostatic gel of propolis-containing and preparation method thereof | |
| CN1241578C (en) | Skin-care medicine with functions of relieving-itching, fully eliminating-toxins and curing-tinea, and its prepn. method | |
| CN1927160A (en) | Gargle and its preparing process | |
| CN1251738C (en) | Chinese medicine for treating ashen nail and its preparation method | |
| CN1954866A (en) | Medicine for treating odontopathy and its preparation method | |
| CN1557286A (en) | Compound chlorhexidine acetate spray | |
| CN1128614C (en) | Use of dichlorobenzyl alchol for preparing a preparation for topical treatment of inflammation and preparation containing dichlorobenzyl alchol | |
| CN101040957A (en) | Medicine for treating skin diseases such as eczema and dermatitis and the method for preparing the same | |
| CN1883620A (en) | Gel agent for treating superficial mycotic infection and method for preparing same | |
| CN1191066C (en) | Externally-used disinfector | |
| CN1095377C (en) | Medicine for treating skin ringworm and dermatitis and preparation process | |
| CN102973680B (en) | External linimentum for treating superficial fungal infection and preparation method of external linimentum | |
| CN107412344B (en) | Pharmaceutical composition for treating pet skin diseases and preparation method thereof | |
| CN101461850B (en) | Application of Chinese medicinal composition in preparing medicament for treating acne | |
| CN1189206C (en) | Medicine for curing leuconychia and hand-foot ringworm and preparing method thereof | |
| CN1251753C (en) | Externally-applied medicine composition for treating mastoproliferation and its prepn | |
| CN104083406A (en) | Compound disinfectant and preparation method thereof | |
| CN1197595C (en) | Chinese medicine preparation for broad-spectrum inflammation relieving, disinfecting, erosion prevention and muscle growing | |
| CN104906131B (en) | A kind of preparation method preventing and treating lamb stomatitis plaster | |
| CN1644206A (en) | Medicine for treating tinea containing biological alkaline salt and preparation thereof | |
| CN114272240B (en) | Anti-infection compound preparation and application thereof | |
| CN1063632C (en) | External use liniment for curing dermatosis | |
| CN114099632B (en) | Chinese medicinal fermented product and its application in preparing medicine for treating fungal infection dermatosis | |
| CN1244398A (en) | Improved tincture with both Chinese and Western medicines for dermatomycosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |